1. Shelkovnikova TA*, An H, Kukharsky M, Dimasi P, Alexeeva S, Shabir O, Heath PR and Buchman VL (2018) Protective paraspeckle hyper-assembly downstream of TDP-43 loss of function in amyotrophic lateral sclerosis. Molecular Neurodegeneration 13, article number: 30. (10.1186/s13024-018-0263-7
  2. Shelkovnikova TA*, Dimasi P, Kukharsky M, An H, Quintiero A, Schirmer C, Buée L, Galas MC and Buchman VL* (2017) Chronically stressed or stress-preconditioned neurons fail to maintain stress granule assembly. Cell Death and Disease 8, article number: e2788. (10.1038/cddis.2017.199)
  3. Dimasi P, Quintiero A, Shelkovnikova TA*, Buchman VL* (2017) Modulation of p-eIF2α cellular levels and stress granule assembly/disassembly by trehalose. Scientific Reports 7, article number: 44088. (10.1038/srep44088)
  4. Van De Pette M, Tunster SJ, McNamara GI, Shelkovnikova T, Millership S, Benson L, Peirson S, Christian M, Vidal-Puig A, John RM. (2016) Cdkn1c boosts the development of brown adipose tissue in a murine model of Silver Russell Syndrome. PLoS Genetics 12(3), article number: e1005916. (10.1371/journal.pgen.1005916)
  5. Scekic-Zahirovic J, Sendscheid O, El Oussini H, Jambeau M, Sun Y, Mersmann S, Wagner M, Dieterlé S, Sinniger J, Dirrig-Grosch S, Drenner K, Birling MC, Qiu J, Zhou Y, Li H, Fu XD, Rouaux C, Shelkovnikova T, Witting A, Ludolph AC, Kiefer F, Storkebaum E, Lagier-Tourenne C, Dupuis L. (2016) Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. EMBO Journal 35(10), pp. 1077-1097. (10.15252/embj.201592559)
  6. Ninkina N, Connor-Robson N, Ustyugov AA, Tarasova TV, Shelkovnikova TA, Buchman VL. (2015) A novel resource for studying function and dysfunction of α-synuclein: mouse lines for modulation of endogenous Snca gene expression. Scientific Reports 5, article number: 16615. (10.1038/srep16615)
  7. Robinson HK, Deykin AV, Bronovitsky EV, Ovchinnikov RK, Ustyugov AA, Shelkovnikova TA, Kukharsky MS, Ermolkevich TG, Goldman IL, Sadchikova ER, Kovrazhkina EA, Bachurin SO, Buchman VL, Ninkina NN. (2015) Early lethality and neuronal proteinopathy in mice expressing cytoplasm-targeted FUS that lacks the RNA recognition motif. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 16(5-6), pp. 402-409. (10.3109/21678421.2015.1040994)
  8. Kukharsky MS, Quintiero A, Matsumoto T, Matsukawa K, An H, Hashimoto T, Iwatsubo T, Buchman VL*, Shelkovnikova TA* (2015) Calcium-responsive transactivator (CREST) protein shares a set of structural and functional traits with other proteins associated with amyotrophic lateral sclerosis. Molecular Neurodegeneration 10, article number: 20. (10.1186/s13024-015-0014-y)
  9. Peters OM, Shelkovnikova T, Highley JR, Cooper-Knock J, Hortobágyi T, Troakes C, Ninkina N, Buchman VL. (2015) Gamma-synuclein pathology in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology 2(1), pp. 29-37. (10.1002/acn3.143)
  10. Shelkovnikova TA*, Robinson HK, Southcombe JA, Ninkina NN, Buchman VL* (2014) Multistep process of FUS aggregation in the cell cytoplasm involves RNA-dependent and RNA-independent mechanisms. Human Molecular Genetics 23(19), pp. 5211-5226. (10.1093/hmg/ddu243)
  11. Shelkovnikova TA*, Robinson HK, Troakes C, Ninkina NN, Buchman VL* (2014) Compromised paraspeckle formation as a pathogenic factor in FUSopathies. Human Molecular Genetics 23(9), pp. 2298-2312. (10.1093/hmg/ddt622)
  12. Shelkovnikova TA (2013) Modelling FUSopathies: focus on protein aggregation. Biochemical Society Transactions 41(6), pp. 1613-1617. (10.1042/BST20130212) Review.
  13. Shelkovnikova TA, Peters OM, Deykin AV, et al. (2013) Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. Journal of Biological Chemistry 288(35), pp. 25266-25274. ** (10.1074/jbc.M113.492017)
  14. Shelkovnikova TA, Robinson HK, Connor-Robson N, Buchman VL (2013) Recruitment into stress granules prevents irreversible aggregation of FUS protein mislocalized to the cytoplasm. Cell Cycle 12(19), pp. 3194-3202. (10.4161/cc.26241)
  15. Peters OM, Shelkovnikova T, Tarasova T, et al. (2013) Chronic administration of dimebon does not ameliorate amyloid-β pathology in 5xFAD transgenic mice. Journal of Alzheimer's Disease 36(3), pp. 589-596. (10.3233/JAD-130071)
  16. Peters O, Millership S, Shelkovnikova TA, et al. (2012) Selective pattern of motor system damage in gamma-synuclein transgenic mice mirrors the respective pathology in amyotrophic lateral sclerosis. Neurobiology of Disease 48(1), pp. 124-131. (10.1016/j.nbd.2012.06.016)
  17. Bachurin SO, Shelkovnikova TA, Ustyugov AA, et al. (2012) Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice. Neurotoxicity Research 22(1), pp. 33-42. (10.1007/s12640-011-9299-y)
  18. Shelkovnikova TA, Kulikova AA, Tsvetkov PhO, et al. (2011) [Proteinopathies--forms of neurodegenerative disorders with protein aggregation-based pathology]. Molekulyarnaya Biologiya 46(3), pp. 402-415. Review
  19. Shelkovnikova TA, Ustyugov AA, Millership S, et al. (2011) Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice. Neurodegenerative Diseases 8(6), pp. 430-437. (10.1159/000324989)

*Corresponding author; ** Chosen as Paper of the Week and Paper of the Year in Molecular basis of Disease section